NY-JEFFERIES-FINANCIAL
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease.
Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000.
“We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charities globally as this is truly a tragedy that affects all of us and, in particular, those who are most disadvantaged and in the greatest need.
The charities selected are both big and small and represent everything from food banks, child care services, assistance with PPE and other medical supplies, support for front line medical workers, assistance for afflicted military personnel, local teen centers, support for police and fire, workforce training and re-training and many other worthy areas that are most in need. We thank our employees and clients for aiding in the selection of many of these remarkable charities.
Finally, all of us at Jefferies would like to thank all the dedicated professionals working tirelessly on the front line to help those in need. They are the true heroes whom we are honored to help in Peg’s name.”
Contributions in the following amounts will be immediately distributed to these respected organizations:
NYC Mayor’s Fund | Peg’s Cure |
|
$ 150,000 |
All Hands and Hearts |
|
$ 150,000 |
American Heart Association |
$ 150,000 |
|
Bowery Mission |
$ 150,000 |
|
Hackensack Meridian Health Foundation |
$ 150,000 |
|
Houston Police Foundation |
|
$ 150,000 |
International Rescue Committee |
|
$ 150,000 |
Robin Hood Foundation |
|
$ 150,000 |
Strive |
|
$ 150,000 |
The Bass Foundation |
|
$ 150,000 |
World Central Kitchen |
|
$ 150,000 |
We Can #TogetherFromHome |
|
$ 100,000 |
Achievement First |
|
$ 100,000 |
Aktion Deutschland Hilft |
|
$ 100,000 |
Alzheimer’s Association |
|
$ 100,000 |
Ambitious About Autism |
|
$ 100,000 |
Barnardo’s |
$ 100,000 |
|
BMS Family Health and Wellness Center |
|
$ 100,000 |
Bob Woodruff Foundation |
|
$ 100,000 |
Boys & Girls Clubs of the Austin Area |
|
$ 100,000 |
Brewers Community Foundation |
|
$ 100,000 |
Buttle UK |
|
$ 100,000 |
Central Texas Food Bank |
|
$ 100,000 |
Chelsea and Westminster Hospital NHS Foundation Trust |
|
$ 100,000 |
Chrysalis |
$ 100,000 |
|
City Harvest |
$ 100,000 |
|
Citymeals on Wheels |
|
$ 100,000 |
Columbia Children's Hospital |
|
$ 100,000 |
Community Food Bank of New Jersey |
|
$ 100,000 |
Covenant House |
|
$ 100,000 |
Doctors Without Borders |
|
$ 100,000 |
East High – EOP (Education Partnership Organization) |
|
$ 100,000 |
Elmhurst Hospital Charity |
|
$ 100,000 |
Family Promise of Bergen County |
|
$ 100,000 |
FarmLink |
|
$ 100,000 |
Feeding America |
|
$ 100,000 |
Food Bank For New York City |
|
$ 100,000 |
Foodlink |
|
$ 100,000 |
Habitat for Humanity Japan |
|
$ 100,000 |
Hance Family Foundation |
|
$ 100,000 |
Humanity & Inclusion |
|
$ 100,000 |
Hunger Free America |
|
$ 100,000 |
Imperial Health Charity |
|
$ 100,000 |
Kids in Crisis |
|
$ 100,000 |
Kohka Foundation |
|
$ 100,000 |
Lahey Clinic Foundation |
|
$ 100,000 |
Mail Force Charity |
|
$ 100,000 |
Martha’s Table |
|
$ 100,000 |
Médecins Sans Frontières |
|
$ 100,000 |
Memorial Hermann Foundation |
|
$ 100,000 |
My Sister's Place |
|
$ 100,000 |
National Emergencies Trust |
|
$ 100,000 |
Navajo Nation Covid-19 Relief Fund |
|
$ 100,000 |
Nazareth Housing |
|
$ 100,000 |
Neighbourly Community Fund |
|
$ 100,000 |
NHS Charities Together |
|
$ 100,000 |
Northwell Health's COVID-19 Emergency Fund |
|
$ 100,000 |
NYU Langone |
|
$ 100,000 |
Off Their Plate |
|
$ 100,000 |
Oxfam India |
|
$ 100,000 |
Philippine Disaster Resilience Foundation |
|
$ 100,000 |
Red Hook Initiative |
|
$ 100,000 |
Rosetree Trust |
|
$ 100,000 |
Royal College of Nursing Foundation |
|
$ 100,000 |
RVNAhealth |
|
$ 100,000 |
Second Harvest |
|
$ 100,000 |
Sempre Con Voi (Always with You) |
|
$ 100,000 |
St Michael’s House |
|
$ 100,000 |
TBD 1 |
|
$ 100,000 |
TBD 2 |
|
$ 100,000 |
TBD 3 |
|
$ 100,000 |
TCF Bank |
|
$ 100,000 |
The Care Workers Charity |
|
$ 100,000 |
The River Fund New York |
|
$ 100,000 |
The United Way of Central Indiana COVID-19 Relief Fund |
|
$ 100,000 |
The World Health Organization (WHO) |
|
$ 100,000 |
Trinity's Services & Food for the Homeless |
|
$ 100,000 |
The Trussell Trust |
|
$ 100,000 |
UNICEF |
|
$ 100,000 |
UR Medicine Home Care’s Meals on Wheels |
|
$ 100,000 |
URMC COVID-19 Emergency Fund |
|
$ 100,000 |
Valpo Surf Project, Inc. |
|
$ 100,000 |
Volunteers of Legal Service |
|
$ 100,000 |
Our Dream Their Smile |
|
$ 100,000 |
West Side Campaign Against Hunger |
|
$ 100,000 |
Women United in Philanthropy |
|
$ 100,000 |
Women's Center of Greater Danbury |
|
$ 100,000 |
|
|
|
Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005663/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
